

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### ANTISENSE OLIGONUCLEOTIDE ISIS 2922 TARGETS IE-EXPRESSION AND PREVENTS HCMV-IE-INDUCED SUPPRESSION OF TSP-1 AND TSP-2 EXPRESSION

S. Margraf<sup>a</sup>; M. Bittoova<sup>a</sup>; J-U. Vogel<sup>a</sup>; R. Kotchekov<sup>a</sup>; H. W. Doerr<sup>a</sup>; J. Cinatl Jr.<sup>a</sup>

<sup>a</sup> J. W. Goethe University Hospital, Inst. f. Med. Virology, Frankfurt am Main, Germany

Online publication date: 31 March 2001

**To cite this Article** Margraf, S. , Bittoova, M. , Vogel, J-U. , Kotchekov, R. , Doerr, H. W. and Cinatl Jr., J.(2001) 'ANTISENSE OLIGONUCLEOTIDE ISIS 2922 TARGETS IE-EXPRESSION AND PREVENTS HCMV-IE-INDUCED SUPPRESSION OF TSP-1 AND TSP-2 EXPRESSION', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 1425 – 1428

**To link to this Article:** DOI: 10.1081/NCN-100002569

**URL:** <http://dx.doi.org/10.1081/NCN-100002569>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## **ANTISENSE OLIGONUCLEOTIDE ISIS 2922 TARGETS IE-EXPRESSION AND PREVENTS HCMV-IE-INDUCED SUPPRESSION OF TSP-1 AND TSP-2 EXPRESSION**

**S. Margraf,\* M. Bittoova, J-U. Vogel, R. Kotchekov,  
H.W. Doerr, and J. Cinatl, Jr.**

J. W. Goethe University Hospital, Inst. f. Med. Virology,  
Paul Ehrlich-Str. 40, D - 60596 Frankfurt am Main, Germany

### **ABSTRACT**


ISIS 2922, but not ganciclovir (GCV), inhibits HCMV immediate early protein (IE) expression in different infected cell lines and prevents down-modulation of extracellular matrix proteins thrombospondin-1 and -2 induced by IE proteins. While action of ISIS 2922 is mainly due to specific inhibition of IE 2 mRNA, there is also evidence for unspecific effects in terms of inhibition of virus adhesion and penetration.

Human cytomegalovirus (HCMV) pathogenesis may be due to changes of cellular gene expression caused at least in part by HCMV immediate early proteins (IE) (1–7). Targeting of IE by antisense approach represents a treatment strategy to prevent both virus replication (9,10) and alteration of cellular gene expression (2,6–7). Effects of HCMV IE mRNA inhibitor ISIS 2922, a phosphorothioate antisense oligonucleotide, was studied in different cell types.

Human retinal glial cells (HRG) and human foreskin fibroblasts (HFF) cultured in vitro were infected with HCMV AD169 and Hi91, respectively. Mock-infected cultures served as controls. Cells were cultured in the presence of ISIS 2922, a non-complementary homologue (ISIS 26062) and anti-CMV nucleoside analogue ganciclovir (GCV). ISIS oligonucleotides were kindly provided by Isis

---

\*Corresponding author.




**Figure 1.** Effects of ISIS 2922 on IE and LA expression in HFF cells infected with M.O.I. 1-2.

Pharmaceuticals, Inc. (Carlsbad, Ca). For treatment, ISIS oligonucleotides were complexed with cationic liposomes DOTAP (Roche, Mannheim, Germany) according to the instructions given by the producer. Cells were preincubated with DOTAP/ISIS 2922 complex overnight in IMDM supplemented with 0.2% FBS (7,9,10). Before infection, cells were washed 3 times with PBS and virus was added for 1 hr adsorption time. After adsorption, cells were washed and DOTAP/ISIS 2922 complex was added again. Cells were stained for IE after 24 hrs and late protein after 72 hrs.

To detect unspecific blocking of virus entry, HFF cells were preincubated in a 6 well plate with ISIS 2922 and DOTAP mixture overnight, washed 3 times with PBS and infected with a extended virus adsorption time of 4 hrs at a MOI of 1-2. Inhibitor of virus-replication ganciclovir (40 µM, Hoffman-la Roche AG, Grenzach-Wyhlen, Germany) and inhibitor of virus binding dextrane sulfate (10 µg/ml) were added during virus adsorption. Cells were washed 3 times with PBS to remove unbound virus and disturbed by freezing and thawing. Intracellular amount of virus particles was measured as HCMV DNA copies/ml by quantitative RT-PCR (Roche, Mannheim, Germany). Extracellular matrix glycoprotein TSP-1 (3-6) and -2 mRNA level was measured by semi-quantitative RT-PCR (3). Indirect immunofluorescent detection of cell associated TSP-1 and -2 proteins was carried out using specific mouse monoclonal antibodies and fluorescein isothiocyanate conjugated goat anti-mouse IgG as secondary antibodies (Becton Dickinson, CA). Antibodies to IgG were used as control. Fluorescence was determined using Becton Dickinson FACScan and CellQuest software (Becton Dickinson, CA). All experiment were repeated at least 3 times.





**Figure 2.** Effects of ISIS 2922 on adhesion/penetration of HCMV to HFF cells infected with MOI 1-2. Corresponding photographs showing IE stained control.

ISIS 2922 prevented both IE/LA antigen expression and HCMV-induced TSP-1 and -2 down-modulation. GCV and ISIS 26062 had no effect on IE and TSP-1 and -2 expression. In all cell types expression of TSP-1 and TSP-2 mRNA was significantly decreased already 24 hrs pi in HCMV-infected compared to mock-infected (results not shown). Using ISIS 2922 at a concentration of 1  $\mu$ M, it inhibited more than 99% of IEA expression. ISIS 2922 partially inhibited virus adhesion and penetration by 40% in HFF cells ( $97.5 \pm 9.2$  DNA copies/100 cells vs.  $58.5 \pm 5.6$  DNA copies/100 cells;  $p < 0.05$ ) compared to virus control. These findings suggest that a significant part of anti-HCMV effects occurred after virus penetration/adhesion. There were no such unspecific effects using GCV, whereas dextrane sulfate showed only inhibition of virus binding/penetration. Because in vivo HCMV spreads from cell to cell, unspecific inhibition of virus adhesion may be less useful than inhibition of virus gene expression. ISIS 2922, but not GCV, is capable to inhibit IEA in a specific mode of action and therefore prevents IE-derived deregulation of cellular genes, which is partially responsible for pathogenic effects.

Although nonspecific effects of ISIS 2922, as suggested (8), cannot be completely excluded, inhibition of both IE and changes in cellular gene expression demonstrate that inhibition of HCMV IE expression by antisense oligonucleotides is a promising strategy to develop novel therapeutic approaches.



## REFERENCES

1. Stenberg, RM.; *Intervirology*, **1996**; 39, 334–9.
2. Scholz, M.; Vogel J-U.; Blaheta R.; Cinatl J. Jr.; *Monogr Virol*, **1988**; 21, 90–105.
3. Cinatl J. Jr.; Bittoova, M.; Margraf S.; Vogel J-U.; Cinatl J. Sen.; Preiser W.; Doerr H.-W.; *J Infect Dis*, **2000**; 182, 643–51.
4. Jaffe GJ.; *Surf. Ophthalmol*, **1994**; 38, 393–4.
5. Sheibani N.; Sorensen CM.; Cornelius LA.; Frazier WA.; *Biochem Biophys Res Commun*, **2000**; 267, 257–61.
6. Cinatl J. Jr.; Kotchetkov R.; Scholz M.; et al.; *Am J Pathol*, **1999**; 155, 285–92.
7. Cinatl J. Jr.; Kotchetkov R.; Weimer E.; et al.; *J Med Virol*, **2000**; 60, 313–23.
8. De Clercq E.; *Drugs*, **1999**; 57, 381.
9. Anderson, KP.; Fox, MC.; Driver, VB.; Martin, MJ.; Azad, RF.; *Antimicrob Agents Chemother*, **1996**; 40, 2004–11.
10. Azad, RF.; Driver, VB.; Tanaka, K.; Crooke, RM.; Anderson, KP.; *Antimicrob Agents Chemother*, **1993**; 37, 1945–54.



## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002569>